HLB Therapeutics Co.,Ltd.
KOSDAQ 115450.KQ
HLB Therapeutics Co.,Ltd. Current Liabilities for the year ending December 31, 2023: USD 20.58 M
-
HLB Therapeutics Co.,Ltd. Current Liabilities for the year ending December 31, 2022 was USD 46.32 M, a -2.44% change year over year.
-
HLB Therapeutics Co.,Ltd. Current Liabilities for the year ending December 31, 2021 was USD 47.47 M, a 182.04% change year over year.
-
HLB Therapeutics Co.,Ltd. Current Liabilities for the year ending December 31, 2020 was USD 16.83 M, a -67.51% change year over year.
-
HLB Therapeutics Co.,Ltd. Current Liabilities for the year ending December 31, 2019 was USD 51.81 M, a 144.69% change year over year.
| Date | Current Liabilities | Total Non-Current Liabilities | Shareholders' Equity | Long-Term Debt |
|---|
| CEO | Mr. Doug Jang |
| IPO Date | March 26, 2010 |
| Location | |
| Headquarters | Parkview Office Tower |
| Employees | 98 |
| Sector | Health Care |
| Industries | |
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email